These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
601 related articles for article (PubMed ID: 1841751)
1. Endocrine therapy: where do we stand and where are we going? Schröder FH Cancer Surv; 1991; 11():177-94. PubMed ID: 1841751 [TBL] [Abstract][Full Text] [Related]
2. Hormonal therapy of prostate cancer. Labrie F Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672 [TBL] [Abstract][Full Text] [Related]
4. Innovative approaches to the hormonal treatment of advanced prostate cancer. Trachtenberg J Eur Urol; 1997; 32 Suppl 3():78-80. PubMed ID: 9267790 [TBL] [Abstract][Full Text] [Related]
5. Overview of enzyme inhibitors and anti-androgens in prostatic cancer. Geller J J Androl; 1991; 12(6):364-71. PubMed ID: 1769904 [TBL] [Abstract][Full Text] [Related]
6. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist]. Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907 [TBL] [Abstract][Full Text] [Related]
7. Controversies in the management of advanced prostate cancer. Tyrrell CJ Br J Cancer; 1999 Jan; 79(1):146-55. PubMed ID: 10408706 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological studies on androgen suppression in therapy of prostate carcinoma. Sandow J; von Rechenberg W; Engelbart K Am J Clin Oncol; 1988; 11 Suppl 1():S6-10. PubMed ID: 3291602 [TBL] [Abstract][Full Text] [Related]
9. [Keyrole of endocrinology in the victory against prostate cancer]. Labrie F Bull Cancer; 2006 Sep; 93(9):949-58. PubMed ID: 16980238 [TBL] [Abstract][Full Text] [Related]
10. Maximal androgen blockade versus total androgen suppression. Dumez H; Van Poppel H; Baert L; Paridaens R Acta Urol Belg; 1997 Mar; 65(1):49-54. PubMed ID: 9175283 [TBL] [Abstract][Full Text] [Related]
11. [Drug treatment of prostatic carcinoma]. Witjes JA; Debruyne FM Ned Tijdschr Geneeskd; 1997 Sep; 141(39):1855-8. PubMed ID: 9545743 [TBL] [Abstract][Full Text] [Related]
12. Is dehydroepiandrosterone a hormone? Labrie F; Luu-The V; Bélanger A; Lin SX; Simard J; Pelletier G; Labrie C J Endocrinol; 2005 Nov; 187(2):169-96. PubMed ID: 16293766 [TBL] [Abstract][Full Text] [Related]
13. Science behind total androgen blockade: from gene to combination therapy. Labrie F; Bélanger A; Dupont A; Luu-The V; Simard J; Labrie C Clin Invest Med; 1993 Dec; 16(6):475-92. PubMed ID: 8013153 [TBL] [Abstract][Full Text] [Related]
14. Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer. Nishiyama T; Suzuki K; Yamana K; Tonegawa E; Wako K; Takahashi K Expert Rev Anticancer Ther; 2006 Feb; 6(2):259-68. PubMed ID: 16445378 [TBL] [Abstract][Full Text] [Related]
16. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer]. Tsukamoto S; Akaza H Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140 [TBL] [Abstract][Full Text] [Related]
17. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR; Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313 [TBL] [Abstract][Full Text] [Related]
18. Carcinoma of the prostate: general concepts. Rioja LA; Sanz J Semin Oncol; 1991 Oct; 18(5 Suppl 6):2-8. PubMed ID: 1948119 [TBL] [Abstract][Full Text] [Related]
19. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528 [TBL] [Abstract][Full Text] [Related]
20. Endocrine therapy for prostate cancer. Sagalowsky AI Spec Top Endocrinol Metab; 1985; 7():101-29. PubMed ID: 3914094 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]